The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus Patients

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study attempts to examine the effect of oral prostaglandin I2 (Beraprost Na), administered for eight weeks, on the endothelial cell functional disorder among asymptomatic high risk diabetes mellitus patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Collaborator: Astellas Pharma Korea, Inc.
• Treatments: Beraprost; Epoprostenol; Tezosentan

Criteria

Inclusion Criteria:

• Type II diabetes mellitus patient

• Patients with symptoms of a minute peripheral blood flow disorder

Exclusion Criteria:

• Cases with either an already-diagnosed coronary arterial disease or a peripheral vascular disease

• Cases with a history of stroke

• Cases with an abnormal finding of vascular stiffness test (PWV and ABI) and plethysmography of legs (PVR)

• Pregnant women or fertile women with an unclear pregnancy